Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis

Eur J Cancer. 2021 Mar:145:179-182. doi: 10.1016/j.ejca.2020.12.016. Epub 2021 Jan 22.

Authors

Boris Duchemann¹, Johan Pluvy², Bruno Crestani³, Gérard Zalcman², Hilario Nunes⁴

Affiliations

¹ Department of Thoracic and Medical Oncology, Avicenne Hospital, AP-HP, Bobigny, France; Université Paris Sorbonne Nord, UFR Santé, Médecine et Biologie Humaine, Bobigny, France. Electronic address: boris.duchemann@aphp.fr.
² Department of Thoracic Oncology, Bichat - Claude-Bernard Hospital, AP-HP, Paris, France.
³ Department of Pneumology, Bichat - Claude-Bernard Hospital, AP-HP, Paris, France.
⁴ Université Paris Sorbonne Nord, UFR Santé, Médecine et Biologie Humaine, Bobigny, France; Department of Pneumology, Avicenne Hospital, AP-HP, Bobigny, France.

PMID: 33486441
DOI: 10.1016/j.ejca.2020.12.016

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Humans
Idiopathic Pulmonary Fibrosis / complications*
Idiopathic Pulmonary Fibrosis / diagnostic imaging
Immune Checkpoint Inhibitors / adverse effects
Immune Checkpoint Inhibitors / therapeutic use*
Lung Neoplasms / complications
Lung Neoplasms / diagnostic imaging
Lung Neoplasms / drug therapy*
Lung Neoplasms / metabolism
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / immunology
Programmed Cell Death 1 Receptor / metabolism
Retrospective Studies
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
PDCD1 protein, human
Programmed Cell Death 1 Receptor